Natural and Synthetic Phosphodiesterase Inhibitors in 2023 : an Update on the Impact on Neurological and Psychiatric Conditions
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
This Perspective provides an updated overview on the involvement of phosphodiesterase (PDE) isoforms and of the corresponding inhibitors in neurological disorders, including dementia, Parkinson's disease, multiple sclerosis, neuropsychiatric conditions and cerebral ischemia. Particular attention has been dedicated to natural and semi-synthetic compounds. Translation into the clinic of preclinical results, toxicity profile and bioavailability represent the challenging aspects in the development of PDE inhibitors. With the aim of providing the latest updates to the reader, the 2023 contributions in the field were considered for the preparation of this Perspective.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
Mini reviews in medicinal chemistry - (2023) vom: 04. Okt. |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
2023 |
|---|
| Anmerkungen: |
Date Revised 11.10.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.2174/0113895575267412230926055026 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363106162 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363106162 | ||
| 003 | DE-627 | ||
| 005 | 20231226092638.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/0113895575267412230926055026 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1210.xml |
| 035 | |a (DE-627)NLM363106162 | ||
| 035 | |a (NLM)37817520 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Natural and Synthetic Phosphodiesterase Inhibitors in 2023 |b an Update on the Impact on Neurological and Psychiatric Conditions |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 11.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a This Perspective provides an updated overview on the involvement of phosphodiesterase (PDE) isoforms and of the corresponding inhibitors in neurological disorders, including dementia, Parkinson's disease, multiple sclerosis, neuropsychiatric conditions and cerebral ischemia. Particular attention has been dedicated to natural and semi-synthetic compounds. Translation into the clinic of preclinical results, toxicity profile and bioavailability represent the challenging aspects in the development of PDE inhibitors. With the aim of providing the latest updates to the reader, the 2023 contributions in the field were considered for the preparation of this Perspective | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a 2023 | |
| 650 | 4 | |a PDE | |
| 650 | 4 | |a dementia | |
| 650 | 4 | |a natural compounds | |
| 650 | 4 | |a schizophrenia | |
| 650 | 4 | |a semi-synthetic compounds | |
| 773 | 0 | 8 | |i Enthalten in |t Mini reviews in medicinal chemistry |d 2001 |g (2023) vom: 04. Okt. |w (DE-627)NLM121595404 |x 1875-5607 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:04 |g month:10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/0113895575267412230926055026 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 04 |c 10 | ||